Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults (CES-MDD)
Primary Purpose
Major Depressive Disorder
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Sponsored by
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring MDD, Depression, Depressive Disorder, Major Depressive Disorder, Cranial Electrotherapy Stimulation, FW-200
Eligibility Criteria
Inclusion Criteria:
- Age 21-65 years and a resident of the United States of America
- Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder
- Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range)
- Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service
- Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study
- Owns and uses a personal, verifiable email address
- Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed
- Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion
- Willingness to not initiate treatment for a mental health issue during the course of the study
- Fluent in English
- Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence
- In the opinion of the investigator, able to comply with study requirements and complete the study
Exclusion Criteria:
- History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days.
- In the opinion of the investigator, considered high risk of suicide
- Previous hospitalization or institutionalization for mental health condition within one year of study entry
- Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation
- Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry
- Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days
- History of alcohol use disorder or other substance use disorder in the past 12 months
- Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements
- Known history of heart disease
- Known history of trigeminal neuralgia
- Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker
- Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days
- Legally blind and/or deaf and without in-home care service to assist with study participation
- Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation
- Current participation in another investigational study or participated in an investigational study within the past 30 days
- In the opinion of the investigator, may not be able to comply with study requirements
- Any employee, family member, or personal associate of the Sponsor or their designees conducting the study
Sites / Locations
- New York Neuromodulation Medical, PLLC
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Arm Description
The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.
The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
Outcomes
Primary Outcome Measures
Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline.
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Secondary Outcome Measures
Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline.
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Change in the Patient Health Questionnaire-9 (PHQ-9) at Weeks One, Two, and Four Compared to Baseline.
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item scale covering the Diagnostic and Statistical Manual, 5th Edition (DSM-5) for Major Depressive Disorder, with a diagnostic algorithm and score-based assessment of presence and severity of depression. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms.
Change in the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) at Weeks One, Two, and Four Compared to Baseline.
The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) is a 16-item rating scale that assesses nine criterion symptom domains to diagnose a major depressive episode. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms.
Beck Depression Inventory Second Edition (BDI-II) Responder Rate at Four Weeks.
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Full Information
NCT ID
NCT05384041
First Posted
May 12, 2022
Last Updated
May 23, 2023
Sponsor
Fisher Wallace Laboratories
Collaborators
NAMSA, Climb Technologies, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT05384041
Brief Title
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
Acronym
CES-MDD
Official Title
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 28, 2022 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
October 24, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fisher Wallace Laboratories
Collaborators
NAMSA, Climb Technologies, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.
Detailed Description
This prospective, fully remote, randomized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
MDD, Depression, Depressive Disorder, Major Depressive Disorder, Cranial Electrotherapy Stimulation, FW-200
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Pivotal Study
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Remote, randomized, decentralized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal investigation.
Allocation
Randomized
Enrollment
255 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
Arm Type
Active Comparator
Arm Description
The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.
Arm Title
Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Arm Type
Placebo Comparator
Arm Description
The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
Intervention Type
Device
Intervention Name(s)
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
Other Intervention Name(s)
Fisher Wallace Stimulator FW-200, FW-200
Intervention Description
The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
Intervention Type
Device
Intervention Name(s)
Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Intervention Description
The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
Primary Outcome Measure Information:
Title
Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline.
Description
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Time Frame
Change at week two compared to baseline.
Secondary Outcome Measure Information:
Title
Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline.
Description
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Time Frame
Change at weeks one and four compared to baseline.
Title
Change in the Patient Health Questionnaire-9 (PHQ-9) at Weeks One, Two, and Four Compared to Baseline.
Description
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item scale covering the Diagnostic and Statistical Manual, 5th Edition (DSM-5) for Major Depressive Disorder, with a diagnostic algorithm and score-based assessment of presence and severity of depression. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms.
Time Frame
Change at weeks one, two, and four compared to baseline.
Title
Change in the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) at Weeks One, Two, and Four Compared to Baseline.
Description
The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) is a 16-item rating scale that assesses nine criterion symptom domains to diagnose a major depressive episode. The minimum score is 0 and the maximum score is 27, with a higher score indicating more severe depressive symptoms.
Time Frame
Change at weeks one, two, and four compared to baseline.
Title
Beck Depression Inventory Second Edition (BDI-II) Responder Rate at Four Weeks.
Description
The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.
Time Frame
Four weeks following baseline.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 21-65 years and a resident of the United States of America
Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder
Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range)
Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service
Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study
Owns and uses a personal, verifiable email address
Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed
Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion
Willingness to not initiate treatment for a mental health issue during the course of the study
Fluent in English
Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence
In the opinion of the investigator, able to comply with study requirements and complete the study
Exclusion Criteria:
History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days.
In the opinion of the investigator, considered high risk of suicide
Previous hospitalization or institutionalization for mental health condition within one year of study entry
Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation
Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry
Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days
History of alcohol use disorder or other substance use disorder in the past 12 months
Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements
Known history of heart disease
Known history of trigeminal neuralgia
Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker
Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days
Legally blind and/or deaf and without in-home care service to assist with study participation
Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation
Current participation in another investigational study or participated in an investigational study within the past 30 days
In the opinion of the investigator, may not be able to comply with study requirements
Any employee, family member, or personal associate of the Sponsor or their designees conducting the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyle Lapidus, MD, PhD
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Neuromodulation Medical, PLLC
City
New York
State/Province
New York
ZIP/Postal Code
10023
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
We'll reach out to this number within 24 hrs